Issue 2, 2018

Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis

Abstract

A novel series of phenithionate analogues or derivatives were designed and synthesized using phenithionate as the lead compound, and their bioactivities were studied. Their structures were confirmed by 1H NMR, 13C NMR, HR-ESI-MS, and elemental analysis, respectively. The results of in vitro inhibitory activity measurement proved that compounds 5a, 5c, 5g, 5i, 5m and 5o had a better inhibitory effect on larva and imago schistosoma. Among them, the inhibitory activity of compound 5i for larva schistosoma was IC50 = 5.21 ± 0.04 μg mL−1, and for imago schistosoma it was IC50 = 6.35 ± 0.08 μg mL−1. Moreover, the experimental results of in vivo anti-schistosomiasis activity measurement showed that they had good anti-schistosomiasis activity. Therefore, these compounds had better drugability.

Graphical abstract: Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis

Article information

Article type
Research Article
Submitted
21 Nov 2017
Accepted
11 Dec 2017
First published
22 Dec 2017

Med. Chem. Commun., 2018,9, 328-336

Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis

S. Zhou and G. Huang, Med. Chem. Commun., 2018, 9, 328 DOI: 10.1039/C7MD00590C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements